Aradigm News

AllPennyStocks.com Announces November 23rd to November 27th U.S. Penny Stocks 2 Watch 11/20/2009 MISSISSAUGA, ON, November 20, 2009 -- AllPennyStocks.com Media, Inc.

Main Category: Respiratory / Asthma Also Included In: Infectious Diseases / Bacteria / Viruses Article Date: 18 Nov 2009 Aradigm Corporation announced that the first patient was dosed in a 6-month, multicenter, international Phase 2 clinical trial of a novel version of inhaled ciprofloxacin in 40 adult patients with non-cystic fibrosis ...

Aradigm Corporation today announced it is presenting data from its Phase 1 and Phase 2a studies at the ERS Annual Congress in Vienna, Austria, September 12-16, 2009.

I'I I'IsIYI I I©I I- I I I IYI - BW - Aradigm Receives Orphan Drug Designation for Inhaled Liposomal Ciprofloxacin to Treat Cystic Fibrosis in Europe Aug.

I'I I'IsIYI I I©I I- I I I IYI - BW - Aradigm Receives Orphan Drug Designation for Inhaled Liposomal Ciprofloxacin to Treat Cystic Fibrosis in Europe Aug.

I'I I'IsIYI I I©I I- I I I IYI - BW - Aradigm Receives Orphan Drug Designation for Inhaled Liposomal Ciprofloxacin to Treat Cystic Fibrosis in Europe Aug.

New York, NY -- AlumiFuel Power Corporation ; The Marketing Alliance, Inc. ; Aradigm Corporation StockProfiler.US is Introducing Leading Microcap Companies! We welcome Investors to sign up and subscribe to our FREE Newsletter at www.stockprofiler.us. Please follow our thread on www.twitter.com at StockProfilerUS ...

I'I I'IsIYI I I©I I- I I I IYI - BW - Aradigm Receives Orphan Drug Designation for Inhaled Liposomal Ciprofloxacin to Treat Cystic Fibrosis in Europe Aug.

Aradigm Corporation today announced that Zogenix, Inc. and Astellas Pharma US, Inc.

I find it odd that Aradigm Corporation stock price dropped the day after Zogenix, Inc.

Aradigm Corporation today announced it received clearance from the U.S. Food and Drug Administration for its inhaled liposomal ciprofloxacin Investigational New Drug application.

Aradigm Corp. said Thursday it received clearance from the U.S. Food and Drug Administration for its inhaled liposomal ciprofloxacin Investigational New Drug application.

Reported revenue of $1.12 billion decreased 16 percent from the second quarter of - MALVERN, Pa.-- --USA Technologies issued the following letter to Shareholders today: Dear Shareholder, - 07/23/2009 - 07:00 AM Spectranetics Reports Second Quarter Revenue of $29 Million COLORADO SPRINGS, Colo.-- --Spectranetics Corporation today reported financial ...

Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on Aradigm Corporation .

On Wednesday, traders on the International Securities Exchange bought to open 7,532 calls - CINCINNATI-- --The wave of questionable economic data washing over Wall Street during the past month has had a chilling effect on the retailing sector.

Main Category: Headache / Migraine Also Included In: Regulatory Affairs / Drug Approvals Article Date: 17 Jul 2009 Aradigm Corporation announced that Zogenix, Inc.

Juli This could be a great catch. The article is taken from zacks homepage. Kronborg http://www.zacks.com/stock/news/21271/Aradigm%92s+Pipeline+Undervalued Aradigma s Pipeline Undervalued By: Jason Napodano, CFA June 19, 2009 ALXA MNKD ALKS Print Share Aradigm Corp .

We like the product pipeline, specifically the inhaled Cipro product for BE and CF, but more visibility is needed before we can recommend investment in the name.

Jun 11, 2009 - Aradigm Corporation today announced it is presenting data from its Phase 1 study in healthy volunteers and Phase 2a study of inhaled liposomal ciprofloxacin in cystic fibrosis patients at the 32nd European Cystic Fibrosis Conference in Brest, France.